Geron says new analyses support RYTELO dosing in lower-risk myelodysplastic syndromes

Bitget2026/11/04 14:09

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Geron will present six research posters at the American Society of Hematology meeting, scheduled for December 12-16, 2026, in New Orleans.
New analyses support Rytelo’s approved dosing regimen in lower-risk myelodysplastic syndromes, according to the company.
Presentations include updated IMproveMF trial results evaluating imetelstat with ruxolitinib in myelofibrosis, alongside research in other blood cancers.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Geron Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611040900PRIMZONEFULLFEED9870032) on November 04, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Geron says new analyses support RYTELO dosing in lower-risk myelodysplastic syndromes

You may also like

Crypto prices